Overview

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Status:
Recruiting

Trial end date:
2022-04-30

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of TQ-B3139 versus crizotinib in subjects with ALK-positive NSCLC that have received one chemotherapy regimen and have not received ALK inhibitor.

Phase:

Phase 3

Details

Lead Sponsor:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Treatments:

Crizotinib
Protein Kinase Inhibitors